K. C. Sourris and J. M. Forbes, “Interactions between Advanced Glycation End-Products (AGE) and Their Re- ceptors in the Devel-opment and Progression of Diabetic Nephropathy Are These Receptors Valid Therapeutic Targets,” Current Drug Targets, Vol. 10, No. 1, 2009, pp. 42-50. doi:10.2174/138945009787122905

has been cited by the following article:

• TITLE: Protective Effects of Danggui Buxue Tang on a Human Umbilical Vein Endothelialcell Damage Induced by Advanced Glycation End Products

  AUTHORS: Wenyu Qin, Bao He, Yu Bei, Rushang Wang, Lang Feng, Youhua Xu, Jiaxiao Zhu, Zhaoguang Zheng, Quan Zhu, Hong Nie

  KEYWORDS: Danggui Buxue Tang (DBT); AGEs; Negative Charge; Apoptosis; Proteinuria; Diabetic Nephropathy

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.2, April 25, 2012

  ABSTRACT: Advanced glycation end products (AGEs) have been regarded as a pivotal inducer in diabetes and kinds of diabetic nephropathy. The present studies explored the effects of Danggui Buxue Tang (DBT) that is a Chinese medicinal de- coction on negative charge to Human Umbilical Vein Endothelial Cell (HUVEC) and the related mechanism. Alcian blue staining was established to evaluate the intensity of negative charge on HUVEC. Proteoglycan expressions of AGP and avidin were determined by SDS-PAGE. We observed that DBT can significantly increase negative charge on HU-VEC and up-regulated AGP and avidin expressions and ameliorate AGEs-induced HUVEC apoptosis. Therefore, all results showed DBT had prevention effects against the progression of AGEs-induced damage, and this decoction might be promising agent against proteinuria in diabetic nephropathy.